Fundraise

Qingshi Yongjun raises hundreds of millions of yuan for brain-chip therapy

What's the deal? Shenzhen-based Qingshi Yongjun closed a Series A round of several hundred million yuan in November 2026, led by Shenzhen Capital Group. The company develops high-end neuromodulation medical devices built around brain-computer interface technology, targeting depression and other brain diseases.

Who's in? Puhua CapitalDealroom has a profile for this one. Try Dealroom →, Green Pine Capital Partners, Oriental Jiafu, and Longtian Capital joined as new backers. Existing shareholders Shenzhen High-Tech InvestmentDealroom has a profile for this one. Try Dealroom →, Yinxinggu CapitalDealroom has a profile for this one. Try Dealroom →, and Oufang Venture Capital added to their stakes.

What's the money for? The funds will go mainly toward registered clinical trials for its neuromodulation devices and Class III medical device filings. Qingshi Yongjun has built an integrated operation spanning research, production, and sales.

Why now? China's brain-computer interface sector is shifting from research toward clinical registration and commercialisation. NeuracleDealroom has a profile for this one. Try Dealroom →'s movement-function product has won approval, and NeuroXess recently closed a US$96.3M Series B to push multi-centre trials and mass production.

What's different here? Most approved implantable brain-computer interface products serve patients with motor dysfunction. Qingshi Yongjun is instead aiming at brain diseases such as depression — an earlier-stage path with higher regulatory and efficacy-validation hurdles.

What could go wrong? Treatment products for brain diseases remain in research and clinical stages, far from approval and large-scale use. The round size alone does not prove the product is close to clinical or commercial success.

The signal: Investor appetite for brain-computer interface startups is rising, and this round funds one of the harder, less-proven therapeutic routes. It signals capital moving beyond motor-function devices toward treating brain disease itself.

Read more: itbear.com.cn

Image credit: "Neurobionics — Minimally Invasive Deep Brain Stimulation" by jurvetson, licensed under CC BY 2.0

More top stories